Pharmacogenomics & Personalized Medicine is a premier open-access journal published by DOVE MEDICAL PRESS LTD, focusing on the vital intersection of pharmacogenomics, pharmacology, and personalized approaches to medicine. Launched in 2008 and based in New Zealand, this journal plays an essential role in disseminating cutting-edge research that aims to enhance therapeutic efficacy through individualized treatment strategies. With its Q3 ranking in both Molecular Medicine and Pharmacology as of 2023, Pharmacogenomics & Personalized Medicine is gaining momentum in the scientific community, providing a platform for researchers to explore significant findings and their implications for patient care. The journal's commitment to open access ensures that valuable information is readily available to a global audience, promoting collaboration and innovation across various fields of health science. We invite researchers, professionals, and students to contribute and explore groundbreaking studies that pave the way for advancements in personalized healthcare.

Lifestyle Genomics is a premier open-access journal published by KARGER, based in Switzerland, that bridges the crucial intersection of Food Science, Genetics, and Medicine. Launched in 2008, it aims to disseminate cutting-edge research that explores the intricate relationship between lifestyle factors and genomic influences on health and wellbeing. With an impressive 2023 impact factor reflected in its ranking in the second quartile of Food Science and medicine fields, as well as a noteworthy position in the third quartile for Genetics, the journal is recognized as an influential platform for engaging insights and innovations. The journal is dedicated to facilitating the exchange of knowledge among researchers, healthcare professionals, and students, fostering collaboration and advancing our understanding of personalized medicine. Operating under an open-access model, Lifestyle Genomics ensures that its research is accessible to a global audience, empowering the scientific community to contribute to transformative discoveries that enhance human health.

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

Genetics Research, published by HINDAWI LTD, is a distinguished open access journal that has been at the forefront of genetic studies since its inception in 1960. With the transition to open access in 2019, this journal has expanded its accessibility, fostering knowledge dissemination across the global scientific community. Operating out of the United Kingdom, it provides a platform for innovative research in the fields of genetics and molecular biology, encompassing a broad range of topics that are highly relevant to medical sciences. As of 2023, it holds a Q4 classification in Genetics and a Q3 classification in miscellaneous Medicine, reflecting its ongoing commitment to scholarly excellence amidst shifting academic landscapes. While the journal's H-index remains unlisted, its indexed ranking within Scopus, with a rank of #325/328 in the Genetics category highlights the challenges ligated to its niche audience. Nevertheless, it serves as a crucial resource for researchers, professionals, and students eager to contribute to and stay informed on the latest genetic research trends and breakthroughs.

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

HUMAN GENETICS, published by SPRINGER, stands as a cornerstone journal in the field of genetics, offering a wealth of research insights since its inception in 1964. Hailing from Germany, this esteemed journal boasts an impressive Q1 ranking in both Genetics and Clinical Genetics, marking it among the top quartile of journals in these categories for 2023. With a notable Scopus rank of #7 in Clinical Genetics and a percentile ranking of 93, HUMAN GENETICS attracts significant attention from researchers and professionals dedicated to advancing our understanding of genetic influences on human health and disease. Although it does not currently offer Open Access options, the journal provides a critical platform for scholarly communication, aimed at disseminating groundbreaking findings in genetics and biotechnology. As the field evolves, HUMAN GENETICS continues to play an instrumental role in bridging the gap between laboratory research and clinical application, making it an essential resource for students and seasoned researchers alike.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.

The Journal of Hepatocellular Carcinoma is a pivotal open-access publication dedicated to advancing the field of hepatocellular carcinoma research. Published by DOVE MEDICAL PRESS LTD since 2014, this journal seeks to disseminate high-quality articles that explore innovative treatments, clinical trials, and emerging research in the context of liver cancer. With its ISSN: N/A and E-ISSN: 2253-5969, the journal is optimized for a global audience, ensuring accessibility to a broad spectrum of researchers, healthcare professionals, and students engaged in oncology and hepatology. While its Scopus ranking places it in the lower quartiles of the respective fields, the journal continues to strive for growth and visibility in a rapidly evolving landscape. The Journal of Hepatocellular Carcinoma is an essential resource for anyone seeking to enhance their understanding of liver diseases and contribute to the fight against hepatocellular carcinoma.

Human Genome Variation, published by SpringerNature, is an esteemed open access journal dedicated to the field of genetic research and exploration. Since its inception in 2014, the journal has been at the forefront of advancing our understanding of human genome diversity and its implications in health and disease. With an E-ISSN of 2054-345X, it features a diverse array of studies that encompass biochemistry, genetics, and molecular biology, making it an invaluable resource for researchers and professionals alike. The journal holds a Q3 ranking in both biochemistry and genetics, and a Q4 ranking in molecular biology, highlighting its growing influence within these disciplines. As the landscape of genomics continues to evolve, Human Genome Variation serves as a platform for the dissemination of high-quality research, fostering collaboration and innovation within the scientific community. Researchers and academics are invited to contribute to this pivotal journal, which not only provides open access to its content since 2014 but also aims to bridge the gap between basic research and clinical applications in genetics.

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.